DOCSLIB.ORG

Hemp'din LLC 2506 Cottage Row Road Cedar Falls, IA, 50613 319

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hemp'din LLC 2506 Cottage Row Road Cedar Falls, IA, 50613 319 RIN 1117-AB53/Docket No. DEA-500 Hemp’dIn LLC 2506 Cottage Row Road Cedar Falls, IA, 50613 319-231-6683 Mr. Timothy J. Shea Via Email Acting Administrator U.S. Drug Enforcement Agency 7000 Army-Navy Dr. Arlington, VA 22202 Washington, DC RE: RIN 1117-AB53/Docket No. DEA-500 Comments to the U.S. Drug Enforcement Agency’s Interim Final Rule Interpreting the Agricultural Improvement Act of 2018 Dear Mr. Shea: We write you to express our formal opposition to the referenced Interim Final Rule (“IFR”) promulgated by the Drug Enforcement Agency (“DEA”) published on August 21, 2020 regarding the DEA’s interpretation of the Agricultural Improvement Act of 20181 (“AIA” or “Farm Bill”). Through the IFR, we believe the DEA is attempting to create new law that is different in spirit and substance from what Congress intended when it passed the AIA. Further, we believe DEA’s attempt to create new law is in violation of Administrative Procedure Act2 (“APA”) and the Controlled Substances Act3 (“CSA”). Accordingly, through this letter, we respectfully request that the DEA withdraw or amend the IFR in order to bring its position in line with the spirit and substance of the APA in particular with 1 AIA, Public Law 115-334, signed December 20, 2018 2 5 U.S.C. § § 702, 706 3 21 U. S. C. § 877 RIN 1117-AB53/Docket No. DEA-500 regard to the legality of intermediate hemp materials and derivatives of hemp such as delta-8 tetrahydrocannabinol (“∆8 -THC”). I. The Agricultural Improvement Act of 2018 The AIA defines hemp as: the plant Cannabis sativa L and any part of that plant… and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of no more than 0.3 percent on a dry weight basis.4 (Emphasis added) It is important to recognize that the AIA defines hemp as any part of the plant, any derivative thereof, any extract thereof and any cannabinoids derived therefrom, amongst others. Therefore, from a regulatory perspective, a C. sativa L. plant part as well as a derivative of that plant part are both defined as “hemp”, so long as the ∆9 -THC concentration is no more than 0.3% dry weight. To be clear, in chemistry, a “derivative” is “a compound that is derived from a similar compound by a chemical reaction.”5 This is distinguished from an analog also known as a structural analog which is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component.6 The AIA amended the Controlled Substances Act so that hemp is now distinguished from marijuana: The term ‘marihuana’ does not include – (i) hemp, as defined in section 1639 of title 7. 7 II. Tetrahydrocannabinoids in Hemp are Not Controlled Substances Pursuant to the AIA, by definition, cannabinoids, of which tetrahydrocannabinoids are a subset, are not controlled substances. ∆8 -THC is a tetrahydrocannabinoid found in hemp. By definition it, like all other cannabinoids derived from hemp, is not a controlled substance under the CSA. 4 7 U.S.C § 1639o(1) 5 See: https://en.wikipedia.org/wiki/Derivative_(chemistry) 6 See: https://en.wikipedia.org/wiki/Structural_analog 7 21 U.S.C § 802 (16)(B). RIN 1117-AB53/Docket No. DEA-500 III. ∆8 -THC is Not a Controlled Substance under the Federal Analogue Act The Federal Analogue Act8 (“AA”) classifies any chemical substance that is “substantially similar” to a controlled substance found in DEA’s Schedule I or II and which “has a stimulant, depressant or hallucinogenic effect on the central nervous system (CNS) that is substantially similar to or greater than”9 (Emphasis added) the controlled substance will be treated the same as if it were on Schedule I when intended for human consumption. ∆8 -THC cannot be classified as an analog of ∆9 -THC because the effect of ∆8 -THC on the CNS is not “substantially similar” to that of ∆9 -THC. It has been documented that, in fact, the CNS effect of ∆8 -THC on a subject is equivalent to about 66% of the CNS effect of ∆9 -THC.10 Two- thirds of the effect cannot be considered “substantially similar to or greater than”. Congress, through legislation, can at some future date determine that, notwithstanding the comparison to ∆9 -THC, ∆8 -THC should be restricted in some way. Or Congress can decide that the definition of a “substantially similar” analogue – for purposes of the AA- shall mean at least 66% of the CNS effect as a controlled substance. But until this happens, ∆8 -THC does not meet the definition of analogue under the AA because it falls outside the definition of “substantially similar”. What DEA cannot do is create new laws merely by labeling them as “interpretations” of an existing law, in this case the Farm Bill. Doing so is a violation of the Administrative Procedure Act and the Controlled Substances Act. 8 21 U.S.C § 813 9 Id. 10 L. E. Hollister, H. K Gillespie, Delta-8-and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration, Clin. Pharmacol. Ther., May-June 1973; 14(3): 353-7. RIN 1117-AB53/Docket No. DEA-500 IV. Conclusion Through the IFR, we believe the DEA is attempting to create new law that is different in spirit and substance from what Congress intended when it passed the AIA. Further, we believe DEA’s attempt to create new law is in violation of Administrative Procedure Act11 (“APA”) and the Controlled Substances Act12 (“CSA”). Accordingly, we respectfully request that the DEA withdraw or amend the IFR in order to bring its position in line with the spirit and substance of the APA in particular with regard to the legality of intermediate hemp materials and derivatives of hemp such as delta-8 tetrahydrocannabinol (“∆8 -THC”). Sincerely, Corey Coleman Corey Coleman CEO [email protected] CC: Edgar J. Asebey, Esq. Asebey Life Science Law PLLC 11 5 U.S.C. § § 702, 706 12 21 U. S. C. § 877 .
Load more

Recommended publications
  • State of New York in Senate
    STATE OF NEW YORK ________________________________________________________________________ 2692 2021-2022 Regular Sessions IN SENATE January 22, 2021 ___________ Introduced by Sen. ORTT -- read twice and ordered printed, and when printed to be committed to the Committee on Codes AN ACT to amend the penal law, in relation to the criminalization of selling, using or possessing synthetic drugs The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The penal law is amended by adding a new section 220.66 to 2 read as follows: 3 § 220.66 Criminal sale, use or possession of synthetic drugs and other 4 similar compounds. 5 A person is guilty of the criminal sale, use or possession of synthet- 6 ic drugs and other similar compounds when they knowingly and unlawfully 7 sell, use and/or possess any synthetic drug, unless such synthetic drug 8 has been expressly prescribed to such person by a physician, psychia- 9 trist or person otherwise duly licensed and authorized to prescribe 10 medication within New York state, and at the time of the alleged 11 violation, the person in possession of the synthetic drug is able to 12 provide written proof to the law enforcement officer that the synthetic 13 drug was so prescribed. Each such violation shall constitute a separate 14 and distinct offense. For purposes of this section: 15 1. "synthetic drug" shall mean any product, whether described as 16 tobacco, potpourri, herbs, incense, spice, aromatic, bath salts, 17 synthetic marijuana, synthetic stimulant
    [Show full text]
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
    [Show full text]
  • Phenibut Addiction in a Patient with Substance Use Disorder
    Open Access Case Report DOI: 10.7759/cureus.5230 Phenibut Addiction in a Patient with Substance Use Disorder Kan Hong Zheng 1 , Afra Khan 1 , Eduardo D. Espiridion 2 1. Miscellaneous, West Virginia School of Osteopathic Medicine, Lewisburg, USA 2. Psychiatry, Frederick Memorial Hospital, Frederick, USA Corresponding author: Kan Hong Zheng, [email protected] Disclosures can be found in Additional Information at the end of the article Abstract Phenibut, a γ-aminobutyric acid (GABA) analog, is a synthetic, nootropic GABAB receptor agonist used to treat anxiety, insomnia, alcohol withdrawal, and other conditions. The drug is licensed and widely used in Russia however, phenibut can be purchased through online vendors in other countries. The current literature on the effects of phenibut intoxication and withdrawal in humans is limited. In this case report, a 23-year-old male with a history of heavy phenibut and alcohol use presented to the emergency department with suicidal thoughts, somatic complaints, and seeking help with detoxification. His history and physical revealed symptoms indicative of alcohol withdrawal, but the extended period of his symptoms suggested an additive effect of his phenibut use. This unique case report illustrates how concurrent and heavy use of phenibut with alcohol may contribute to an extended and exacerbated withdrawal syndrome. Categories: Psychiatry, Public Health Keywords: phenibut, beta phenyl gamma aminobutyric acid, gaba, nootropic drug, alcoholism, alcohol withdrawal, substance use Introduction Nootropic drugs that can enhance cognitive function are becoming increasingly popular and available for purchase on the Internet. Phenibut, 4-amino-3-phenyl-butyric acid, is an analog of the γ-aminobutyric acid (GABA) neurotransmitter with an additional phenyl group that enhances diffusion across the blood-brain-barrier [1].
    [Show full text]
  • A Non-Computer Method Used to Determine a Structural Analog Associated with Xerostomia Among Diverse Species of Drugs: Speculation Based on Molecular Models
    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1980 A Non-Computer Method Used to Determine a Structural Analog Associated with Xerostomia Among Diverse Species of Drugs: Speculation Based on Molecular Models Patrick J. Angelo Jr. Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Oral Biology and Oral Pathology Commons Recommended Citation Angelo, Patrick J. Jr., "A Non-Computer Method Used to Determine a Structural Analog Associated with Xerostomia Among Diverse Species of Drugs: Speculation Based on Molecular Models" (1980). Master's Theses. 3079. https://ecommons.luc.edu/luc_theses/3079 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1980 Patrick J. Angelo Jr. A NON-COMPUTER METHOD USED TO DETERMINE A STRUCTURAL ANALOG ASSOCIATED WITH XEROSTOMIA AMONG DIVERSE SPECIES OF DRUGS. SPECULATION BASED ON MOLECULAR MODELS by Patrick J. Angelo, Jr. A Thesis Submitted to the Faculty of the Graduate School o£ Loyola University of Chicago in Partial Fulfillment of the Requirements for the Degree of Master of Science June 1980 ·; (.,' ' ' •• - ,.:__ • .:_'_.:__ ·~--'/.-.: .!.. DEDICATION To my parents, Patrick and Frances Angelo Sr., my wife Kimberly Ann (Burgess) Angelo, and inlaws Jack and Mary Burgess, for their encouragement, support and understanding. ii ACKNOWLEDGMENTS I wish to thank the members of my advisory committee Dr.
    [Show full text]
  • Addiction Medicine - Substances of Abuse
    INTENSIVE UPDATE AUGUST 24 - 26, 2018 & BOARD REVIEW Loews Chicago O’Hare Hotel Rosemont, IL INNOVATIVE • COMPREHENSIVE • HANDS-ON Addiction Medicine - Substances of Abuse Bradley J. Miller, DO, FAAFP The American College of Osteopathic Family Physicians is accredited by the American Osteopathic Association Council to sponsor continuing medical education for osteopathic physicians. The American College of Osteopathic Family Physicians designates the lectures and workshops for Category 1-A credits on an hour-for-hour basis, pending approval by the AOA CCME, ACOFP is not responsible for the content. Substances of Abuse ACOFP Intensive Update and Board Review in Osteopathic Family Medicine Bradley J. Miller, DO, FAAFP Williamsport Family Medicine Residency Objectives • Define Addiction • Review current statistics and disease burden of substance abuse in the United States. • Review DSM V criteria for substance use disorders • Review specific substances of abuse (opioids, alcohol, nicotine, MJ) and accepted behavioral and pharmacologic treatments 1 What Is Addiction: ASAM Definition1 Short Definition of Addiction Addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by substance use and other behaviors. Without treatment or engagement in recovery activities, addiction is progressive and can result in
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Mike's Smoke, Cigar & Gifts, Petitioner/ Appellant V. City of St
    Brigham Young University Law School BYU Law Digital Commons Utah Court of Appeals Briefs (2007– ) 2016 Mike's Smoke, Cigar & Gifts, Petitioner/ Appellant v. City of St. George, Respondent/ Appellee. Utah Court of Appeals Follow this and additional works at: https://digitalcommons.law.byu.edu/byu_ca3 Part of the Law Commons Original Brief Submitted to the Utah Supreme Court; digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, Brigham Young University, Provo, Utah. Recommended Citation Brief of Appellant, Mikes Smoke cibar v St George, No. 20151030 (Utah Court of Appeals, 2016). https://digitalcommons.law.byu.edu/byu_ca3/3129 This Brief of Appellant is brought to you for free and open access by BYU Law Digital Commons. It has been accepted for inclusion in Utah Court of Appeals Briefs (2007– ) by an authorized administrator of BYU Law Digital Commons. Policies regarding these Utah briefs are available at http://digitalcommons.law.byu.edu/ utah_court_briefs/policies.html. Please contact the Repository Manager at [email protected] with questions or feedback. IN THE UTAH COURT OF APPEALS MIKE'S SMOKE, CIGAR & GIFTS, Petitioner/ Appellant Case No. 20151030-CA V. CITY OF ST. GEORGE, Respondent/Appellee. On appeal from the order of the Fifth District Court for Washington County, the Honorable Jeffrey C. Wilcox presiding. ADDENDUM TO APPELLANT'S OPENING BRIEF Bryan J. Pattison Thomas J. Burns DURHAM JONES & PINEGAR, P.C. 192 E. 200 N., Third Floor St. George, UT 84770 Telephone: (435) 674-0400 Attorneys for Respondent/Appellee Ryan L. Holdaway, USB #14058 Shawn M. Guzman Diane Pitcher, USB #12626 Paula J.
    [Show full text]
  • Critical Review Report: ADB-FUBINACA
    Critical Review Report: ADB-FUBINACA Expert Committee on Drug Dependence Forty-first Meeting Geneva, 12-16 November 2018 This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 41st ECDD (2018): ADB-FUBINACA © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • ( 12 ) United States Patent
    US009737531B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 737 ,531 B2 Javitt ( 45) Date of Patent : Aug . 22 , 2017 ( 54 ) COMPOSITION AND METHOD FOR 2008 /0194698 A1 * 8 / 2008 Hermanussen et al. .. .. 514 /662 TREATMENT OF DEPRESSION AND 2011/ 0207776 A18 / 2011 Buntinx 2011 /0306586 Al 12 / 2011 Khan PSYCHOSIS IN HUMANS 2012 /0041026 A12 / 2012 Waizumi (71 ) Applicant : Daniel C Javitt , Bardonia , NY (US ) FOREIGN PATENT DOCUMENTS ( 72 ) Inventor: Daniel C Javitt, Bardonia , NY (US ) CN 101090721 12 / 2007 KR 2007 0017136 A 2 / 2007 ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee, NJ (US ) WO WO 2005 /000216 A2 1 / 2005 WO WO 2005 /065308 A2 7 / 2005 ( * ) Notice : Subject to any disclaimer , the term of this WO WO 2005 /079756 9 / 2005 patent is extended or adjusted under 35 WO 2011044089 4 / 2011 U . S . C . 154 ( b ) by 0 days . wo WO 2012 / 104852 Al 8 / 2012 ( 21 ) Appl. No. : 13 /936 , 198 OTHER PUBLICATIONS Ceglia et al. , “ The 5 -HT2A receptor antagonist M100 , 907 prevents ( 22 ) Filed : Jul. 7 , 2013 extracellular glutamate rising in response to NMDA receptor block ade in the mPFC ,” Journal of Neurochemistry , 2004 , 91 , 189 - 199 . * ((65 65 ) Prior Publication Data Mony et al. , “ Identification of a novel NR2B -selective NMDA US 2014 / 0018348 A1 Jan . 16 , 2014 receptor antagonist using a virtual screening approach , ” Bioorganic & Medicinal Chemistry Letters 20 ( 2010 ) 5552 - 5558 . * Ceglia et al ., “ The 5HT2A receptor antagonist M100 , 907 prevents Related U . S . Application Data extracellular glutamate rising in response to NMDA receptor block ( 60 ) Provisional application No .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 3-Fluoromethcathinone, a Structural Analog of Mephedrone, Inhibits Growth and Induces Cell Cycle Arrest in Ht22 Mouse Hippocampal Cells
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2014, 65, 2, 241-246 www.jpp.krakow.pl K. SIEDLECKA-KROPLEWSKA1, A. SZCZERBA1, A. LIPINSKA2, T. SLEBIODA1, Z. KMIEC1 3-FLUOROMETHCATHINONE, A STRUCTURAL ANALOG OF MEPHEDRONE, INHIBITS GROWTH AND INDUCES CELL CYCLE ARREST IN HT22 MOUSE HIPPOCAMPAL CELLS 1Department of Histology, Medical University of Gdansk, Gdansk, Poland; 2Department of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland Recently, the abuse of recreational drugs has become an important problem in many countries. Among these psychoactive substances are synthetic cathinones, a group of compounds derived from the alkaloid cathinone, that have gained widespread popularity. Many cathinones have demonstrated neurotoxic effects. The aim of this study was to examine the effects of 3-fluoromethcathinone, a structural analog of mephedrone, on HT22 mouse hippocampal cells. Cell viability was assessed using the sulforhodamine B assay. Flow cytometry was used to study the cell cycle distribution. We found that 3-fluoromethcathinone inhibits growth of HT22 cells. Our results also revealed that it induces G0/G1-phase cell cycle arrest. To our knowledge, this is the first study to demonstrate the cytotoxic action of 3- fluoromethcathinone. Our findings suggest that abuse of this cathinone derivative may not be without risk. Key words: 3-fluoromethcathinone, cathinones, recreational drugs, legal highs, mouse hippocampal cells INTRODUCTION confusion (6, 13, 15-30). Cathinones are often combined with other psychoactive substances, such as cannabis, MDMA (3,4- Recently, synthetic cathinones have gained widespread metylenedioxymethamphetamine) as well as alcohol (6). There popularity as a new group of recreational drugs.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]